Medications
How retatrutide dosing appears in clinical trials
A research-framed summary of how retatrutide has been dosed in published trials. Retatrutide is investigational and not available by prescription.
6 min read · Updated 2026-05-27
Peptide GPS publishes educational information, not medical advice. We don't sell, prescribe, or recommend specific medications, dosages, or providers. Always discuss any therapy with a licensed clinician.
Key takeaways
- Retatrutide has no approved clinical dose because it is not approved.
- Published trial arms used gradual weekly escalation to a target dose.
- Trial-arm numbers are research data, not a prescription to self-administer.
Why this is framed as ''in trials''
is not and is not available by prescription.
There is no established clinical dosing because there is no approved . The only structured dosing information that exists comes from the trial protocols themselves.
Trial design pattern
trials tested several once-weekly dose arms against .
All arms began at a low and escalated over a number of weeks before reaching the target arm dose.
Escalation was gradual for the same reason as other incretin drugs — to manage gastrointestinal side effects.
What the trials reported
Higher target dose arms showed larger average weight reduction at 48 weeks than lower arms.
Gastrointestinal side effects were the most common adverse events and were generally most pronounced during escalation.
Full trial-arm details are published in the New England Journal of Medicine and on ClinicalTrials.gov.
What this is not
These are not a dosing recommendation. They were administered under medical supervision, with monitoring, in a controlled study population.
Vials sold online as ''retatrutide'' are not the trial drug, are not verified for identity or purity, and are not legal to use as medicines.
If retatrutide becomes approved, official prescribing information will set actual clinical dosing — which may look very different from any single trial arm.
Get the weekly brief
One plain-English email per week on GLP-1s, peptides, and the regulation around them.